No announcement yet.

STUDY: No proinflammatory signature after SCT

  • Filter
  • Time
  • Show
Clear All
new posts

  • STUDY: No proinflammatory signature after SCT

    No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients


    Lutterotti A, Jelcic I, Schulze C, Schippling S, Breiden P, Mazzanti B, Reinhardt S, Di Gioia M, Repice A, Massacesi L, Sputtek A, Salinas-Riester G, Kroeger N, Sospedra M, Saccardi R, Zander A, Martin R; Multiple Sclerosis (Jan 2012)

    Autologous hematopoietic stem cell transplantation (aHSCT) has been used as a therapeutic approach in multiple sclerosis (MS). However, it is still unclear if the immune system that emerges from autologous CD34+ hematopoietic progenitor cells (HPC) of MS patients is pre-conditioned to re-develop the proinflammatory phenotype.

    The objective of this article is to compare the whole genome gene and microRNA expression signature in CD34+ HPC of MS patients and healthy donors (HD). CD34+ HPC were isolated from peripheral blood of eight MS patients and five HD and analyzed by whole genome gene expression and microRNA expression microarray. Among the differentially expressed genes (DEGs) only TNNT1 reached statistical significance (logFC=3.1, p<0.01). The microRNA expression was not significantly different between MS patients and HD. We did not find significant alterations of gene expression or microRNA profiles in CD34+ HPCs of MS patients.

    Our results support the use of aHSCT for treatment of MS.
    Dave Bexfield